TG Therapeutics (TGTX) to Release Quarterly Earnings on Wednesday

TG Therapeutics (NASDAQ:TGTX) is projected to release its earnings data before the market opens on Wednesday, February 26th. Analysts expect TG Therapeutics to post earnings of $0.08 per share and revenue of $100.67 million for the quarter.

TG Therapeutics Price Performance

NASDAQ TGTX opened at $31.16 on Wednesday. The business’s fifty day moving average price is $31.10 and its 200-day moving average price is $27.59. The stock has a market capitalization of $4.85 billion, a price-to-earnings ratio of -311.57 and a beta of 2.26. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. TG Therapeutics has a 1-year low of $12.84 and a 1-year high of $36.84.

Insiders Place Their Bets

In other TG Therapeutics news, CFO Sean A. Power sold 10,021 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the sale, the chief financial officer now owns 660,611 shares in the company, valued at approximately $18,847,231.83. This represents a 1.49 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 10.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms have recently weighed in on TGTX. HC Wainwright reissued a “buy” rating and set a $55.00 price target on shares of TG Therapeutics in a report on Wednesday, January 15th. StockNews.com cut TG Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, January 31st. The Goldman Sachs Group raised their target price on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. JPMorgan Chase & Co. raised their target price on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a report on Monday, November 25th. Finally, TD Cowen assumed coverage on TG Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 target price on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. According to MarketBeat, TG Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $40.67.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.